Article | Outcome | Average pre-treatment | Mean after treatment | Difference of averages | Follow-up after 1 year | (%) | Follow-up ≥ 2 years | (%) | Follow-up ≥ 3 years | (%) |
---|---|---|---|---|---|---|---|---|---|---|
Scheffler et al./2014 [18] | Go-Gn/Sn Overbite LAFH U6-PP L6-Go-Gn L1-MP U1-PP | NR NR NR NR NR NR NR | NR NR NR NR NR NR NR | − 1.2 (1.0) 2.2 (1.6) − 1.6 (2.2) − 2.3 (1.4) 0.6 (1.6) NR 0.1 (3.8) | 0.0 (0.9) − 0.3 (0.8) − 0.2 (1.4) 0.5 (1.1) − 0.6 (1.3) NR − 0.3 (1.0) | – – – – – – – | 0.0 (0.8) − 0.4 (1.1) − 0.3 (1.4) 0.5 (1.2) − 0.3 (1.3) NR − 0.3 (1.2) | – – – – – – – | NR NR NR NR NR NR NR | – – – – – – – |
Baek et al./2010 [15] | SN-Go Me Overbite AFH U6-PP L1-MP U1-PP | 45.44 (4.11) − 3.91 (1.65) 133.95 (5.55) 26.88 (1.12) 43.58 (2.46) 31.50 (2.67) | 43.41 (4.41) 1.65 (0.82) 131.41 (6.10) 24.50 (1.64) 45.17 (2.78) 32.56 (2.12) | − 2.03 (1.59) 5.56 (1.94) − 2.53 (1.90) − 2.39 (1.76) 1.59 (2.10) 1.05 (1.40) | 43.68 (4.88) 0.66 (0.79) * 131.86 (5.54) 24.89 (1.69) * 44.90 (2.58) 32.49 (1.91) | (13%) (17%) (16%) (16%) (17%) (6%) | NR NR NR NR NR NR | – – – – | 43.98 (4.76) 0.45 (1.09) * 132.32 (5.87) 24.94 (1.68) * 45.12 (2.57) 32.83 (2.15) | (28%) (21%) (35%) (18%) (3%) (26%) |
Sugawara et al./2002 [14] | MP/FH Overbite LAFH L6-MP U6-PP L1-MP U1-PP | 33.1 (2.1) − 2.8 (1.68) 76.1 (5.8) 35.7 (4.1) 34.0 (3.0) 44.5 (3.9) 29.8 (3.1) | 31.7 (2.4) 2.1 (0.8) 74.6 (6.0) 33.9 (4.1) 25.0 (2.8) 45.8 (4.1) 30.9 (3.3) | − 1.3 (NR) 4.9 (NR) − 1.5 (NR) − 1.8 (NR) 1.0 (NR) 1.3 (NR) 1.1 (NR) | 32.2 (3.0)* 1.2 (0.8)* 75.2 (5.8)* 34.2 (4.4)* 25.1 (2.5)* 45.3 (4.3) 30.7 (3.1) | (38%) (18%) (40%) (16%) (10%) (38%) (18%) | NR NR NR NR NR NR NR | – – – – – – – | NR NR NR NR NR NR NR | – – – – – – – |
Deguchi et al./2011 [19] | Overbite MP/SN U6-PP L6-MP LAFH L1-MP U1-PP | − 4.4 (1.2) 45.8 (6.0) 26.9 (3.0) 36.0 (2.5) 74.7 (5.9) 46.3 (3.4) 32.4 (2.3) | 1.8 (1.1) 42.2 (6.7) 24.6 (2.5) 35.2 (1.9) 72.2 (5.1) 46.6 (2.8) 33.4 (2.3) | 6.2 (1.7) − 3.6 (2.1) − 2.3 (1.3) − 0.8 (1.3) − 2.6 (2.5) 0.3 (2.3) 1.0 (1.6) | NR NR NR NR NR NR NR | – – – – – – – | 1.0 (0.9)* 43.8 (6.5)* 25.1 (2.8)* 37.0 (1.9)* 72.2 (5.1)* 46.3 (3.1) 33.4 (2.3) | (12%) (44%) (21%) (225%) (0%) (100%) (0%) | NR NR NR NR NR NR NR | – – – – – – – |
Marzouk et al./2015 [20] | Overbite N-S-Gn U6-pp L6-MP L1-MP U1-PP | − 4.75 (2.27) 77.09 (3.01) 28.27 (2.55) 34.43 (1.27) 44.05 (2.79) NR | 2.18 (0.48) 74.68 (2.67) 25.23 (2.14) 34.86 (1.35) 45.62 (2.82) NR | 6.93 (1.99) − 2.23 (0.37) − 3.04 (0.79) 0.43 (0.53) 1.57 (0.07) NR | 1.61 (0.42) 75.39 (2.83)* 25.54 (2.17)* 34.57 (1.13) 45.32 (2.80) NR | (8%) (31%) (10%) (67%) (19%) NR | NR NR NR NR NR NR | – – – – – – | 1.41 (0.39) 75.69 (2.89) 25.64 (2.17) 34.29 (1.38) 45.56 (2.82) NR | (11%) (45%) (13%) (132%) (4%) NR |
Lee et. al/2008 [21] | MeGo/SN Overbite AFH U6-PP L1-MP U1-PP | 44.9 (1.7) − 3.7 (1.7) 133.4 (5.4) 26.7 (1.2) NR 31.30 (2.46) | 42.9 (4.5) 1.7 (0.7) 130.8 (5.7) 24.5 (1.7) NR 32.30 (1.94) | 3.9 (− 2.0) 5.4 (1.8) − 2.6 (1.9) − 2.2 (1.7) NR 1 (1.21) | 43.0 (4.8)* 0.7 (0.7)* 131.1 (5.4)* 24.7 (1.6)* NR 32.25 (1.88) | (2.5%) (18%) (11%) (9%) NR (5%) | NR NR NR NR NR NR | – – – – – – | NR NR NR NR NR NR | – – – – – – |